Roflumilast, a phosphodiesterase‐4 (PDE4) inhibitor, may be effective for treating refractory oral ulcers (OUs) in BD and RAS, especially in regions where apremilast is unavailable. This evidence concerns the gene PDE4A and Behcet disease.